BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boos LA, Leslie I, Larkin J. Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:739-53. [PMID: 32401070 DOI: 10.1080/13543784.2020.1769066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Reference Citation Analysis]
2 Niebel D, Fröhlich A, Zarbl R, Fietz S, de Vos L, Vogt TJ, Dietrich J, Sirokay J, Kuster P, Saavedra G, Ramírez Valladolid S, Hoffmann F, Strieth S, Landsberg J, Dietrich D. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clin Epigenetics 2022;14:50. [PMID: 35410311 DOI: 10.1186/s13148-022-01270-2] [Reference Citation Analysis]